We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.18 | -1.27% | 91.90 | 91.45 | 92.00 | 94.03 | 91.33 | 93.99 | 1,753,124 | 02:01:49 |
From May 2019 to May 2024
By Rumman Ahmed
BANGALORE--Indian drug maker Cipla Ltd. (500087.BY) Thursday said it has lost an appeal in a U.S. court over a patent case related to a pet drug.
A lower U.S. court had in June last year ordered the seizure of pet drug PetArmor Plus made by Cipla and Velcera Inc. (VLCR) after ruling the drug violated a patent held by Merial, a unit of French giant Sanofi (SNY), covering Frontline Plus.
The U.S. court of appeals for the federal circuit in Washington D.C. affirmed the order of the district court, Middle District of Georgia, Cipla said in a statement to the stock exchanges.
The district court hasn't yet determined any financial implication of the patent infringement, Cipla said.
Cipla, which was manufacturing the drug on behalf of Velcera, said it was examining options for appealing against the latest order.
Write to Rumman Ahmed at rumman.ahmed@dowjones.com
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
